MDGL
Madrigal Pharmaceuticals, Inc.
536.86
1 x 534.29
1 x 531.85
bid
ask
+
5.86
1.10%
1 @ 06:44 PM
536.80 -0.06 (0.01%)
| Ytd | -7.81% | |
| 1y | 67.84% |
522.70
day range
538.80
286.44
52 week range
615.00
| Open | 526.26 | Prev Close | 531.00 | Low | 522.70 | High | 538.80 | Mkt Cap | 12.38B |
| Vol | 241.71K | Avg Vol | 327.79K | EPS | -13.50 | P/E | N/A | Forward P/E | 43.35 |
| Beta | -1.06 | Short Ratio | 8.54 | Inst. Own | 106.99% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 511.73 | 200-d Avg | 500.38 | 1yr Est | 678.71 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-06 | 2026-03 | 0 | N/A | 0.36 | 9.97% |
| 2026-02-19 | 2025-12 | 0.04 | N/A | -2.61 | -6.00% |
| 2025-11-04 | 2025-09 | 0 | N/A | -3.1 | -156.57% |
| 2025-08-05 | 2025-06 | 0 | N/A | 1.58 | 45.40% |
| 2025-05-01 | 2025-03 | 0 | N/A | 0.3 | 8.29% |
| 2025-02-26 | 2024-12 | 0 | N/A | 1.41 | 34.22% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-11 | B of A Securities | Upgrade | Neutral | Neutral |
| 2026-05-13 | Truist Securities | Upgrade | Buy | Buy |
| 2026-05-07 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-05-07 | Evercore ISI Group | Upgrade | Outperform | Outperform |
| 2026-05-06 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-02-20 | B of A Securities | Upgrade | Neutral | Neutral |
Profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-16 | BAKER BROS ADVISORS, L.P. | Unknown | 0.00 | Stock Award(Grant) |
| 2025-03-12 | CRAVES FREDERICK B | Director | 383.55K | Conversion of Exercise of derivative security |
| 2026-03-05 | DIER MARDI C | Chief Financial Officer | 12.49K | Sale |
| 2026-01-08 | FRIEDMAN PAUL A | Director | 842.70K | Conversion of Exercise of derivative security |
| 2026-03-05 | HUNTSMAN CAROLE A | Officer | 12.69K | Sale |
| 2026-03-05 | KELLEY SHANNON T | General Counsel | 12.14K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Baker Bros Advisors LP | 2.14M | 0.00 | 9.29% |
| 2026-03-30 | HHG PLC | 2.02M | 0.00 | 8.76% |
| 2026-03-30 | RTW INVESTMENTS, LLC | 1.99M | 0.00 | 8.65% |
| 2026-03-30 | venBio Select Advisor LLC | 1.82M | 0.00 | 7.89% |
| 2025-12-30 | Vanguard Group Inc | 1.81M | 0.00 | 7.85% |
| 2026-03-30 | BlackRock Inc | 1.56M | 0.00 | 6.77% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-04-29 | Vanguard Total Stock Mkt Idx Inv | 587.99K | 0.00 | 2.55% |
| 2026-03-30 | Vanguard Health Care Inv | 444.14K | 0.00 | 1.93% |
| 2026-03-30 | Janus Henderson Forty S | 429.42K | 0.00 | 1.86% |
| 2026-03-30 | Janus Concentrated Growth CF | 429.42K | 0.00 | 1.86% |
| 2026-04-29 | Vanguard Small Cap Index | 422.81K | 0.00 | 1.83% |
| 2026-05-28 | iShares Russell 2000 ETF | 409.15K | 0.00 | 1.77% |
Split
| Split | Date |
|---|---|
| 1 : 35 | 2016-07-25 |